Insulin detemir har jämförts med NPH-insulin. Behandlingsstudier visar inga egentliga skillnader

Hans Liedholm, Agneta Bjorck Linné

Research output: Contribution to journalArticlepeer-review

1 Citation (SciVal)


To investigate the evidence behind supposed advantages of insulin detemir over existing therapy (NPH insulin), we carried out a systematic review. We analysed the available documentation presented after registration of the drug by the European drug regulatory authority (EMEA) and approached the data presented at the authority's Internet site. Some data from Food and Drug Administraion (FDA) contributed. All published studies not included in the registration file were also included in the analysis. Data on glycaemic control, expressed as HbA1c, hypoglycaemia, and change in body weight were registered. Quality of life - a secondary endpoint infrequently investigated - was considered. All studies included a comparison with NPH insulin, incorporating both type 1 and type 2-diabetes. There was no consistent difference between the two insulin treatments regarding HbA1c, nor was there any evidence concerning differences regarding hypoglycaemia, except instances of mild nocturnal hypoglycaemia. These cases were not adequately reported, however. A small change in body weight in favour of insulin detemir was detected. No data on quality of life was identified.
Original languageEnglish
Pages (from-to)1417-1426
Issue number18
Publication statusPublished - 2006

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Psychiatry/Primary Care/Public Health (013240500)

Subject classification (UKÄ)

  • Clinical Medicine


Dive into the research topics of 'Insulin detemir har jämförts med NPH-insulin. Behandlingsstudier visar inga egentliga skillnader'. Together they form a unique fingerprint.

Cite this